Exome Asset Management logo

Exome Asset Management

North America, New York, United States, New York

Description

Exome Asset Management is an asset management company focused on investing in public markets across the worldwide healthcare industry.

Investor Profile

Exome Asset Management has made 5 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Post Ipo Equity (40%)
  • Series D (40%)
  • Series Unknown (20%)

Country Focus

  • United States (40%)
  • China (40%)
  • Sweden (20%)

Industry Focus

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Medical
  • Personal Health
  • Medical Device
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Exome Asset Management frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 1
Nantahala Capital Management
North America, Connecticut, United States, New Canaan
Co-Investments: 1
Adage Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 1
Dafna Capital Management
North America, California, United States, Los Angeles
Co-Investments: 1
Sphera Global Healthcare Fund
Asia, Tel Aviv, Israel, Tel Aviv
Co-Investments: 1
Pivotal Life Sciences
North America, California, United States, San Francisco
Co-Investments: 1
Logos Capital
North America, California, United States, San Francisco
Co-Investments: 1
SC
North America, Oregon, United States, Bend
Co-Investments: 1
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 1
Eli Lilly
North America, Indiana, United States, Indianapolis
Co-Investments: 1

Which angels does Exome Asset Management often collaborate with?

SI
North America, New York, United States, New York
Shared Deals: 1

What are some of recent deals done by Exome Asset Management?

Aprea

Stockholm, Stockholms Lan, Sweden

Aprea is a biopharmaceutical company that develops novel cancer therapeutics.

BiotechnologyHealth CareMedicalPersonal HealthPharmaceutical
Post Ipo EquityMar 11, 2024
Amount Raised: $16,000,000
Gracell Biotechnologies

Suzhou, Jiangsu, China

Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.

BiotechnologyHealth CareMedical
Post Ipo EquityAug 7, 2023
Amount Raised: $100,000,000
IMPACT Therapeutics

Nanjing, Jiangsu, China

IMPACT Therapeutics is a therapeutics company dedicated to the development of similar drugs to treat cancer.

BiotechnologyPharmaceuticalTherapeutics
Series DMar 14, 2022
Broncus Technologies

Mountain View, California, United States

Broncus Technologies is a medical technology company developing minimally-invasive medical devices for emphysema and other lung diseases.

BiotechnologyHealth CareMedicalMedical Device
Series DJan 28, 2021
Centrexion Therapeutics

Boston, Massachusetts, United States

Centrexion Therapeutics is a late clinical-stage biopharmaceutical company addressing the treatment of chronic pain.

BiotechnologyHealth CarePharmaceutical
Series UnknownOct 29, 2020
Amount Raised: $40,500,000